Predicting PD-L1 expression status in patients with non-small cell lung cancer using [¹⁸F]FDG PET/CT radiomics.

ABSTRACT:

Background

In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the available ICI therapy strategies, programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors are the most widely used worldwide. At present, immunohistochemistry (IHC) is the main method to detect PD-L1 expression levels in clinical practice. However, given that IHC is invasive and cannot reflect the expression of PD-L1 dynamically and in real time, it is of great clinical significance to develop a new noninvasive, accurate radiomics method to evaluate PD-L1 expression levels and predict and filter patients who will benefit from immunotherapy. Therefore, the aim of our study was to assess the pre

SUBMITTER: Zhao X 

PROVIDER: S-EPMC9868196 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature